Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
In this article, we discuss the 10 meme stocks that more than doubled in 2021. If you want to skip our detailed analysis of these stocks, go directly to the 5 Meme Stocks that More than Doubled in 2021. Meme stocks have exploded in popularity at the stock market. According to a study by investment […]
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
The stock market is full of ups and downs, which isn’t necessarily a bad thing. Shares of clinical-stage biotechnology company Cassava Sciences (NASDAQ:SAVA) are prone to peaks and valleys, but this means that you can trade SAVA stock profitably if you have good timing. Source: Pavel Kapysh / Shutterstock.com Don’t get the wrong idea — you can also hold Cassava shares long-term if you believe in the company. After all, Cassava Sciences is one of the more interesting companies using science to ad
Cassava Sciences is now conducting phase 3 trials for its lead drug candidate, an Alzheimer's treatment called simufilam. Skeptics of the company's research want the FDA to halt those trials to investigate claims of data manipulation. President and CEO Remi Barbier sounded defiant in a recent announcement: "We stand committed to translate what we believe is a promising scientific breakthrough into a potentially meaningful treatment for people with Alzheimer’s disease. The rest is noise.”
Cassava Sciences Inc (NASDAQ: SAVA) has initiated a second Phase 3 study of simufilam in patients with Alzheimer's disease. The second Phase 3 study is designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg over 78 weeks over 78 weeks in approximately 1,000 patients. Cassava Sciences' is conducting the Phase 3 program in Alzheimer's under Special Protocol Assessments (SPA) from the FDA. The first Phase 3 RETHINK-ALZ study is designed to evaluate the safety and efficacy o
Biogen's (BIIB) regulatory application seeking approval for its Alzheimer's drug, Aduhelm, in Europe hits setback as it receives negative trend vote from the CHMP.